Search Results for: 95

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

October 23, 2023 07:00 ET -Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies- -Key Opinion Leader (KOL) webinar featuring expert oncologist Ricard Mesia M.D., Ph.D., to be held today, Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md., […]

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 Read More »

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

October 16, 2023 08:00 ET -Results from investigator-sponsored study in collaboration with the Institut Catala d’Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader (KOL) webinar featuring expert oncologist Ricard Mesia M.D., Ph.D., to be held Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md., Oct. 16,

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Read More »

Theriva™ Biologics anuncia la presentación en el Congreso ESMO 2023 de los resultados de supervivencia del estudio de fase 1 que evalúa el VCN-01 en combinación con durvalumab en pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente

October 16, 2023 08:00 ET – Los resultados del estudio patrocinado por investigadores en colaboración con el Instituto Catalán de Oncología (ICO) muestran una mayor supervivencia de los pacientes, correlacionada con la regulación al alza inducida por el VCN-01 de PD(L)-1 – – El seminario web Key Opinion Leader (KOL) con el destacado oncólogo Dr.

Theriva™ Biologics anuncia la presentación en el Congreso ESMO 2023 de los resultados de supervivencia del estudio de fase 1 que evalúa el VCN-01 en combinación con durvalumab en pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023

August 09, 2023 12:43 ET – Inicio de la dosificación en centros de EE. UU. de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Las segundas dosis de VCN-01 intravenoso administradas a pacientes en España fueron bien toleradas y presentaron un perfil de

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023 Read More »

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

August 08, 2023 08:00 ET – Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials – -VIRAGE remains on

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

– Initiated dosing at U.S. sites for VIRAGE – – Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated – – VIRAGE remains on track to complete enrollment in the first quarter of 2024 – ROCKVILLE, Md., Aug. 02, 2023 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma Read More »

Theriva™ Biologics anuncia avances clave en VIRAGE, un ensayo multinacional de fase 2b en curso de VCN-01 en combinación con quimioterapia en adenocarcinoma ductal pancreático

August 02, 2023 15:57 ET – Inicio de la dosificación en centros de EE. UU. para VIRAGE –– Administración de la segunda dosis de VCN-01 intravenoso a pacientes en España, que fue bien tolerada –– VIRAGE sigue avanzando para completar la inscripción en el primer trimestre de 2024 – ROCKVILLE, Md., Aug. 02, 2023 (GLOBE

Theriva™ Biologics anuncia avances clave en VIRAGE, un ensayo multinacional de fase 2b en curso de VCN-01 en combinación con quimioterapia en adenocarcinoma ductal pancreático Read More »

Theriva Biologics anuncia la designación de fármaco huérfano concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas

June 28, 2023 15:35 ET ROCKVILLE, Maryland, June 28, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la Administración de Alimentos y Medicamentos (FDA) de

Theriva Biologics anuncia la designación de fármaco huérfano concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas Read More »

Theriva™ Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

ROCKVILLE, Md., June 27, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lead clinical candidate VCN-01,

Theriva™ Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer Read More »

Theriva™ Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 23, 2023 08:00 ET -Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)- ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to

Theriva™ Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery Read More »